Related Experiment Videos
Bone marrow transplantation in Hunter syndrome
E J McKinnis1, S Sulzbacher, J C Rutledge
1Department of Pediatrics, University of Washington School of Medicine, Seattle, USA.
The Journal of Pediatrics
|July 1, 1996
Summary
Bone marrow transplants do not halt neurocognitive decline in Hunter syndrome (mucopolysaccharidosis II). This treatment failed to prevent disease progression in a child with the severe form of this rare genetic disorder.
Area of Science:
- Genetics
- Metabolic Disorders
- Hematology
Background:
- Hunter syndrome (mucopolysaccharidosis II) is a rare X-linked disorder impacting mucopolysaccharide metabolism.
- The condition typically leads to severe intellectual disability and premature death.
Observation:
- A child diagnosed with Hunter syndrome underwent a successful allogeneic bone marrow transplant from an HLA-identical sibling at 29 months old.
- Engraftment was confirmed and sustained for 70 months post-transplantation without immediate complications.
Findings:
- Despite successful engraftment, the patient's neurocognitive abilities continued to decline.
- Bone marrow transplantation did not prevent the neurological progression of Hunter syndrome.
Implications:
- This case suggests that replacing defective marrow-derived macrophages is insufficient to halt neurological deterioration in severe Hunter syndrome.
- Further research is needed to explore alternative or adjunctive therapies for the neurological manifestations of Hunter syndrome.